GlassScriptPhysician profile
Raghuveer Vanguru
NPI 1700891579
$4,106.32
in general payments reported to CMS, 2019-2025
23 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $57.12 · 2021: $408 · 2022: $442 · 2023: $289 · 2024: $1,230 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $519.70 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $482.13 | 2021-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $478.66 | 2020-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.92 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $378.82 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $300.53 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $217.36 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $187.72 | 2019-2025 | Jynarque |
| Scpharmaceuticals INC. | $175.05 | 2025 | |
| Glaxosmithkline, LLC. | $146.26 | 2022 | |
| Ardelyx, INC. | $132.99 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Travere Therapeutics, INC. | $126.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $125.89 | 2024-2025 | |
| Amgen INC. | $101.56 | 2022-2024 | Tavneos |
| Fresenius USA Marketing, INC. | $54.49 | 2024 | Velphoro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $52.59 | 2024-2025 | Terlivaz, Acthar |
| Daiichi Sankyo INC. | $38.30 | 2021 | |
| Potrero Medical, INC. | $29.01 | 2021 | |
| Apellis Pharmaceuticals, INC. | $25.75 | 2025 | Empaveli |
| Renalytix Ai, INC. | $20.39 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ultragenyx Pharmaceutical INC. | $19.53 | 2024 | Crysvita |
| Akebia Therapeutics INC | $18.16 | 2021 | |
| Nevro Corp. | $13.39 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raghuveer Vanguru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.